Bone disease in multiple myeloma: pathophysiology and management. - Test2 - elhamkhani - TriplyDB

Bone disease in multiple myeloma: pathophysiology and management.

Bone disease in multiple myeloma: pathophysiology and management.

http://www.wikidata.org/entity/Q34045789

about

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.Dickkopf-1 negatively regulates the expression of osteoprotegerin, a key osteoclastogenesis inhibitor, by sequestering Lrp6 in primary and metastatic lytic bone lesions Plasma cell leukemia: from biology to treatment.Bone Pain and Muscle Weakness in Cancer Patients.Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review.Targeting the Bone Marrow Microenvironment.An Evidence-Based Approach to Myeloma Bone Disease.The Critical Role of Imaging in the Management of Multiple Myeloma.Surgical Roles for Spinal Involvement of Hematological Malignancies.A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma The Role of the Chemokine System in Tissue Response to Prosthetic By-products Leading to Periprosthetic Osteolysis and Aseptic Loosening.N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.Pathological Fracture in Odontoid Process in Multiple Myeloma.Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.Panoramic and skull imaging may aid in the identification of multiple myeloma lesions.New agents in the Treatment of Myeloma Bone Disease.MMSA-1 expression pattern in multiple myeloma and its clinical significance.Membrane translocation of Bruton kinase in multiple myeloma cells is associated with osteoclastogenic phenotype in bone metastatic lesions.Q58736053

P2860

Q28077635-853539D2-6EBA-42C2-8E3F-88CFA85872F4 Q33918020-9AF34BEA-F321-4027-A39A-FA632323F1FC Q35605900-AA71C2E0-AAC1-4C14-AC36-DD6E53FE8D3F Q35955440-4945A448-E722-4475-931A-7EA8C3775798 Q36029858-B2FB5B68-C17C-4A17-AA53-D98743EA1BFA Q37144501-D17E0D11-6C52-49A2-8D0C-AF0FB2E29091 Q37205581-EE95A977-EF95-443B-96B4-5B8EFC6CF81D Q38380625-188C1DB9-E713-42DA-B3D9-60D0141A7FBB Q38684768-2ACA8703-4EA6-4B5E-9A5C-C19EA4CE9B82 Q38808310-8F3FB739-9C86-4C82-9A71-A483CA000C22 Q38808395-35F0FDBA-7828-4AE8-9CB9-04EC1D644839 Q38970585-485EFBD8-8274-43DF-BDBE-0510FA62B1A5 Q39153978-6CB1C289-1F69-485B-B619-862D314C1999 Q39186780-DCA3FDA5-67C6-4176-9767-A83226BB1F6A Q40053632-44A955F4-EE46-47D3-A75F-57AAA91C7627 Q41091865-59D79B1C-4FA3-40C9-BDC4-017F9BB157B4 Q41370609-54DA2444-F0BE-4385-B836-3B188573C49A Q41537137-C2327291-5B19-4600-B067-1A63B7ED280E Q41586677-FCE7C554-E55D-45AC-98FA-9B3C78F47990 Q42250739-3A3952E8-BB2E-45B5-92AD-C6A8D61C4F7A Q48314232-813C1943-ABA6-4A0C-A425-DE4D00CCB3D1 Q49603272-E45BB0AF-A586-46BD-B238-053F43537839 Q50323850-1D160747-3AC8-45CC-85DD-41DF040A0A7C Q52907776-59A93031-13A8-4DE0-94D1-4ECE471A7341 Q54983552-AB9ED60A-47D6-4080-BAF2-0C3A2D9332F4 Q58736053-5813D14F-32C9-4A0B-8CA6-61AEE117C78C

P2860

Bone disease in multiple myeloma: pathophysiology and management.

http://www.wikidata.org/entity/Q34045789

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Bone disease in multiple myeloma: pathophysiology and management.

@ast

Bone disease in multiple myeloma: pathophysiology and management.

@en

Bone disease in multiple myeloma: pathophysiology and management.

@nl

type

label

Bone disease in multiple myeloma: pathophysiology and management.

@ast

Bone disease in multiple myeloma: pathophysiology and management.

@en

Bone disease in multiple myeloma: pathophysiology and management.

@nl

prefLabel

Bone disease in multiple myeloma: pathophysiology and management.

@ast

Bone disease in multiple myeloma: pathophysiology and management.

@en

Bone disease in multiple myeloma: pathophysiology and management.

@nl

P1433

Q34045789-8A6AE85C-2845-49C7-80F1-D37BB0FC272D

P1476

Q34045789-3EBDCD27-71F0-4475-A7F0-9301F923A739

P2093

Q34045789-59C86BEE-D6C8-4C7F-9B40-3AED21927C6A

Q34045789-82E10BCB-69A8-4DDF-88F0-A95D4F1059FD

Q34045789-8F1C4772-2ACD-4DE4-A18A-4B6EBB7F2735

Q34045789-9E11A39E-3459-4A75-90F6-C64115E788F2

P2860

Q34045789-0073E40F-2ADF-468D-9AEC-C23BD4659F2A

Q34045789-02AEADEB-32E0-41CD-9816-8AC481B12A18

Q34045789-03CC93EB-5B34-4179-8D8B-C52D31BE3A50

Q34045789-0605F53E-7EFF-4658-B3A3-00F8D97BFDE6

Q34045789-08403657-AE76-4D8C-9284-229163C505E6

Q34045789-1027AD20-5891-492C-A107-EAD7BC0F543B

Q34045789-12745D05-2AEE-4C11-ACD0-A34B17D33814

Q34045789-139D9673-C455-4063-8D74-12824C86CE09

Q34045789-1A600302-F67F-46BA-BBB5-B0A68A486655

Q34045789-1B9F7538-DC2A-40E1-9A43-5DBE31ABB8BC

P304

Q34045789-8DCDB03A-84C6-4FA1-B55A-8D61F2AA5ED9

P31

Q34045789-B7EC0928-6466-48D4-ACC9-95BC69B67B27

P356

Q34045789-9D717FAE-66CA-47EE-A297-18570FA87A6B

P478

Q34045789-1DB86D9F-947A-4C41-B0DE-C227612E6C09

P50

Q34045789-DB41A927-90E4-4D67-8D0A-D6EE587453DC

P577

Q34045789-94569381-12D2-4C33-B64E-8C03809AAD16

P5875

Q34045789-392B4477-9CC4-494B-8C26-C7ABF1516F98

P698

Q34045789-2ED8C950-4DB0-408D-A4AC-D3147C9AB982

P921

Q34045789-FCC2AA63-DE7D-4EDE-8AB9-09D41FF5C881

P932

Q34045789-D074C0EE-CF6E-4682-98D3-CD5318276B2C

P356

P1433

Cancer growth and metastasis

P1476

Bone disease in multiple myeloma: pathophysiology and management

@en

P2093

Abdul Hameed

http://www.w3.org/2001/XMLSchema#string

Jennifer J Brady

http://www.w3.org/2001/XMLSchema#string

Martin Clynes

http://www.w3.org/2001/XMLSchema#string

Peter O'Gorman

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Bisphosphonates: mechanism of action and role in clinical practice

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia

LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

High bone density due to a mutation in LDL-receptor-related protein 5

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

P304

33-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/CGM.S16817

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265344158

http://www.w3.org/2001/XMLSchema#string

P698

25187738

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

4133035

http://www.w3.org/2001/XMLSchema#string